Home・Список акций・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Закрыт

СекторЗдравоохранение

27.59 3.41

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

26.19

Макс.

27.59

Ключевые показатели
By Trading Economics
Доход	1.3M 2.9M
Продажи	-19M 177M
P/E Средняя по отрасли	207.077 68.51
Прибыль на акцию	0.6
Рентабельность продаж	1.644
Сотрудники	825
EBITDA	5M 30M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+17.64% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-40M 1.1B
Предыдущая цена открытия	24.18
Предыдущая цена закрытия	27.59

Новостные настроения

By Acuity

50%

175 / 340 Рейтинг в Healthcare

Pacira Pharmaceuticals Inc-DE График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 19:53 UTC

Pacira Biosciences Inc is higher today, supported by overall market strength and a decline in crude oil prices easing inflation concerns.

3 авг. 2026 г., 20:06 UTC

Pacira Biosciences Inc. shares are higher today, reflecting broader market gains led by major stocks, despite no specific company news identified.

31 июл. 2026 г., 20:02 UTC

Pacira Biosciences Inc's shares are lower today, reaching a session low earlier. The price remains above its 20-day moving average despite the decline.

30 июл. 2026 г., 17:16 UTC

Pacira Biosciences is advancing during Thursday's session, regaining momentum after earlier pulling back from a session high amid broader market optimism.

29 июл. 2026 г., 20:04 UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a decline since Tuesday's close. The stock reached an early high before falling significantly.

28 июл. 2026 г., 19:56 UTC

Event

News

Shares of Pacira Biosciences Inc. are higher, driven by survey findings on orthopedic pain's impact on the workforce and strong interest in non-opioid treatments.

27 июл. 2026 г., 18:51 UTC

Event

News

Pacira Biosciences advances PCRX-201 to commercial manufacturing, allowing patient enrollment in Phase 2 ASCEND study. Shares are higher as investor confidence strengthens.

24 июл. 2026 г., 17:16 UTC

Pacira Biosciences Inc shares are lower today, with no specific news driving the decline. Broader market sentiment is impacted by falling crude oil prices.

22 июл. 2026 г., 18:06 UTC

Pacira Biosciences Inc shares are lower in Wednesday's session, pulling back from earlier gains amid broader market caution and rising crude oil prices.

21 июл. 2026 г., 19:56 UTC

Pacira Biosciences Inc is trading higher, reflecting broader market interest in technology and AI sectors ahead of upcoming earnings reports.

20 июл. 2026 г., 19:46 UTC

Pacira Biosciences Inc shares are trading lower today, having retraced from an earlier high. No specific news was identified to explain the decline.

Сравнение c конкурентами

Изменение цены

Pacira Pharmaceuticals Inc-DE Прогноз

Целевая цена

By TipRanks

17.64% рост

Прогноз на 12 месяцев

Средняя 31.67 USD 17.64%

Максимум 38 USD

Минимум 25 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Pacira Pharmaceuticals Inc-DE на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

Покупка

Удержание

Продажа

Основано на мнении 3 аналитиков, присваивавших рейтинги акциям Pacira Pharmaceuticals Inc-DE – Данные за последние 3 месяца.

Настроения

By Acuity

175 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.